Acute kidney injury post coronary angioplasty

Naik, Sachin; Shukla, Shubham; Sethi, Jasmine; Sekar, Aravind

doi:10.1136/bcr-2022-249294

Cited by 2 publications

(8 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous case reports, the mechanism underlying the interaction has been suggested to be e.g., ticagrelor-induced acute renal impairment leading to decreased excretion of rosuvastatin, or cytochrome P450 (CYP) enzyme-mediated interactions. [2][3][4]7,9,10,12 In 1 of our cases, no kidney injury was observed during the episode of rhabdomyolysis, and in another case, renal function recovered after rosuvastatin cessation and dialysis while ticagrelor was continued. These findings suggest that the possible renal impairment may be a consequence rather than cause of rhabdomyolysis.…”

Section: Discussionmentioning

confidence: 86%

“…In the literature, we found a total of 11 reported cases of rhabdomyolysis during concomitant treatment with ticagrelor and rosuvastatin (Table S4). [2][3][4][5][6][7][8][9][10][11][12] The patients (7 female, 4 male) were aged 49-87 years.…”

Section: Literature Reviewmentioning

confidence: 99%

“…The treatment is usually well tolerated. However, clinicians have reported multiple cases of rhabdomyolysis during concomitant use of rosuvastatin and ticagrelor, [2][3][4][5][6][7][8][9][10][11][12] leading to a growing suspicion of an underlying drug-drug interaction. Three cases were recently identified and are described in this article for the first time.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?

Lehtisalo

Kiander

Filppula

et al. 2023

Brit J Clinical Pharma

View full text Add to dashboard Cite

We present 3 patients diagnosed with rhabdomyolysis 1–6 months after the initiation of concomitant rosuvastatin and ticagrelor medication. A literature review and Food and Drug Administration adverse event reporting system revealed >40 reports of rhabdomyolysis during concomitant ticagrelor and rosuvastatin, including 3 with a fatal outcome. We show that ticagrelor inhibits breast cancer resistance protein‐, organic anion transporting polypeptide (OATP) 1B1‐, 1B3‐ and 2B1‐mediated transport of rosuvastatin in vitro with half‐maximal unbound inhibitory concentrations of 0.36, 4.13, 7.5 and 3.26 μM, respectively. A static drug interaction model predicted that ticagrelor may inhibit intestinal breast cancer resistance protein and thus increase rosuvastatin plasma exposure 2.1‐fold, whereas the OATP‐mediated hepatic uptake of rosuvastatin should not be inhibited due to relatively low portal ticagrelor concentrations. Taken together, concomitant use of ticagrelor with rosuvastatin may increase the systemic exposure to rosuvastatin and the risk of rosuvastatin‐induced rhabdomyolysis. Further studies are warranted to investigate the potential pharmacokinetic interaction between ticagrelor and rosuvastatin in humans.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Literature Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?

Lehtisalo

Kiander

Filppula

et al. 2023

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Although usually well‐tolerated, rosuvastatin can cause muscle symptoms of varying severity, especially at higher doses 1 . Previously published case reports have suggested that concomitant use of rosuvastatin and the platelet‐inhibitor ticagrelor may have led to severe, even fatal, cases of rosuvastatin‐induced rhabdomyolysis 2–13 . Because the risk of rosuvastatin‐induced myotoxicity is concentration‐dependent, the rhabdomyolysis cases suggest a potential pharmacokinetic drug–drug interaction between ticagrelor and rosuvastatin.…”

mentioning

confidence: 99%

“…led to severe, even fatal, cases of rosuvastatin-induced rhabdomyolysis. [2][3][4][5][6][7][8][9][10][11][12][13] Because the risk of rosuvastatin-induced myotoxicity is concentration-dependent, the rhabdomyolysis cases suggest a potential pharmacokinetic drug-drug interaction between ticagrelor and rosuvastatin.…”

mentioning

confidence: 99%

Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

Lehtisalo,

Tarkiainen,

Neuvonen

et al. 2023

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Ticagrelor and rosuvastatin are often used concomitantly after atherothrombotic events. Several cases of rhabdomyolysis during concomitant ticagrelor and rosuvastatin have been reported, suggesting a drug‐drug interaction. We showed recently that ticagrelor inhibits breast cancer resistance protein (BCRP) and organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1 ‐mediated rosuvastatin transport in vitro. The aim of this study was to investigate the effects of ticagrelor on rosuvastatin pharmacokinetics in humans. In a randomized, cross‐over study, nine healthy volunteers ingested a single dose of 90 mg ticagrelor or placebo, followed by a single 10 mg dose of rosuvastatin 1 hour later. Ticagrelor 90 mg or placebo were additionally administered 12, 24, and 36 hours after their first dose. Ticagrelor increased rosuvastatin area under the plasma concentration‐time curve (AUC) and peak plasma concentration 2.6‐fold (90% confidence intervals 1.8‐3.8 and 1.7‐4.0, P=0.001 and P=0.003), and prolonged its half‐life from 3.1 to 6.6 hours (P=0.009). Ticagrelor also decreased the renal clearance of rosuvastatin by 11% (3‐19%, P=0.032). The N‐desmethylrosuvastatin:rosuvastatin AUC0‐10 h ratio remained unaffected by ticagrelor. Ticagrelor had no effect on the plasma concentrations of the endogenous OATP1B substrates glycodeoxycholate 3‐O‐glucuronide, glycochenodeoxycholate 3‐O‐glucuronide, glycodeoxycholate 3‐O‐sulfate, and glycochenodeoxycholate 3‐O‐sulfate, or the sodium‐taurocholate cotransporting polypeptide substrate taurocholic acid. These data indicate that ticagrelor increases rosuvastatin concentrations more than two‐fold in humans, probably mainly by inhibiting intestinal BCRP. Since the risk for rosuvastatin‐induced myotoxicity increases along with rosuvastatin plasma concentrations, using ticagrelor concomitantly with high doses of rosuvastatin should be avoided.

show abstract

Acute kidney injury post coronary angioplasty

Cited by 2 publications

References 5 publications

Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?

Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?

Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

Contact Info

Product

Resources

About